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Summary: A modification of the method developed by Dekinnenjian &Maas ((1970) Anal. Biochem. 55, 113-122)
is described for the determination of 3rmethoxy-4-hydroxyphenylglycol in urine. The use of 4-methoxy-3-hydroxy-
phenylglycol as an internal standard improves the accuracy, simplicity and reproducibility. Therefore, the method is
suitable for routine determination in laboratories without gas chromatography/mass spectrometry equipment. Some
results obtained in depressed patients and healthy controls are presented.
4-Methoxy-3-hydroxyphenylglykol als interner Standard ßr die Bestimmung von 3-Methoxy-4-hydroxyphenylglykol
im Harn:
Ergebnisse bei Patienten mit Depression und gesunden Kontrollpersonen
Zusammenfassung: Zur Bestimmung von 3-Methöxy-4-hydroxyphenylglykol im Harn wird eine Modifikation der
Methode vonDekirmenifan &Maäs ((1970) Anal. Biochem. 35,113—122) beschrieben. Die Verwendung von
4^Methoxy-3-hydroxyphenylglykol als internem Standard verbessert Richtigkeit, Handhabung und Reproduzierbar-
keit. Daher ist die Methode für Routinebestimmungen in Laboratorien ohne Gaschromatographie/Massenspektro-
metrie-Ausjüstung geeignet. Einige Ergebnisse von Patienten mit Depression und gesunden Kontrollen werden mitge-
teilt.
Introduction
The major metabolites of norepinephrine in urine are
3-methoxy-4-hydroxymandelic acid and 3-methpxy-4-
hydroxyphenylglycol. It is assumed that the aldehydes
produced in the metabolism of norepinephrine follow
a predominantly reductive pathway to the glycol in
the central nervous system (2). The average contribu-
tion by brain to the total body production of 3-methoxy-
4-hydroxyphenylglycol is estimated to be 63% in man
(3).
The value of 3^methoxy^4iydroxyphenylglycol deter-
minations for the elucidation of the aetiology of
depressive illness is doubtful, but they may be useful
for classifying depressive disorders and predicting drug
response (4,5).
Materials and Methods
Chemicals and solutions
1.0 mol/1 Acetate buffer pH 6.0
20g/lEDTA
Na2S2Os p. A.
1.0 mol/1 KHC03
NaCl p. A.
Chloroform p. A.
Ethyl acetate p. A. freshly distilled over K2CO3
Pyridine p. A.
Toluene p. A. (all Merck, Darmstadt)
^Glucuronidase/Arylsulfatase, EC 3.2.1.31/3.1.6.1 (Boehringer,
Mannheim)
Pentafluoropropionic anhydride (Pierce, Rotterdam)
3^Methoxy-4-hydroxyphenylglycol piperazine salt (EGA-Chemie,
Steinheim)
4-Methoxy-3-hydroxyphenylgiycol (R. Paesel KG, Frankfurt)
Dimethyidichlorosilane (Fluka, Neu-Ulm)
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Equipment
Gas Chromatograph: Hewlett-Packard 57 30A (ECD, constant
current and variable pulser frequency)
Automatic sampler: Hewlett-Packard 76 71A
Integrator: Hewlett-Packard 33 80A
Treatment of glassware
4 ml glass-stoppered tubes for derivatisation should be silanized
with a solution of 50 g/1 dimethyldichlorosilane in toluene and
then dried overnight at 300 °C. Silanisation should be repeated
every month.
Procedure
Urine sampling
Two or three 24-h urine samples were collected from untreated
in-patients or healthy volunteers. Patients had to meet the
criteria for primary affective disorders as described by Feighner
et al. (6). The criterion for bipolarity was a prior history of
hypomania or mania. After determination of pH and creatinine
(according to the method ofJaffe) 0.5 g/1 sodium disulfite was
added and aliquots were stored at - 20 °C.
Incubation
Since more than 90% of urinary 3-methoxy-4-hydroxyphenyl-
glycol is present in the form of the glucuronide and the sul-
phate (10), extraction had to be preceded by enzymic hydrolysis.
0.2 ml 1.0 mol/1 acetate buffer, 0.1 ml 20 g/l EDTA and 0.2 ml
0-glucuronidase arylsulfatase were added to 0.5 ml urine and
incubated at 37 °C for 24 h. 0.1 ml of a solution of 0.02 g/1
4-methoxy-3-hydroxyphenylglycol in acetate buffer pH 6.0
were added to the hydrolyzed mixture.
In experiments according to procedure a) (described below),
increasing amounts of a solution of 0.01 g/1 3-methoxy-4-
hydroxyphenylglycol (free acid) in acetate buffer pH 6.0 were
also added.
Extraction
The mixture was extracted twice with 2 ml CHC13 and the organic
layer discarded. After addition of 200 mg NaCl, the aqueous
phase was extracted with 2 ml ethyl acetate, while shaking
during one minute on a Vortex mixer. After centrifugation, the
organic phase was carefully removed with a Pasteur pipette. The
extraction was repeated three times. The combined organic
layers were brought to 2 ml at reduced pressure with a rotary
evaporator and then washed with 1 ml 1 mol/1 KHCO3. The
KHC03 layer was re-extracted with 0.5 ml ethyl acetate then
discarded. The organic phases were transferred into the silanized
vials and dried under a stream of nitrogen. (Extracts may be
stored at - 20 °C for some days, provided that they are protected
from moisture.)
Derivatisation
To the vial containing the extract, 0.04 mi f mixture of
pyridine/ethylacetate 1:2000 and 0.05 mi pentafluoropropionic
anhydride was added, the vial was stoppered and the mixture
allowed to react at + 25 °C for one hour. Then, the contents of
the vial were dried under a stream of nitrogen. Since the derivate
is volatile, the nitrogen-stream must be carefully regulated and
stopped immediately after drying. The residue was dissolved in
1 ml ethyl acetate.
Chrornat graphy
1 μΐ of the sample was injected twice on a coiled glass column
10 ft X 4 mm internal diameter, packed with 3% OV-210 on
gaschrom Q 80^100 mesh. The injection port temperature was
250 °C, the temperature of oven and detector 170° and 300 °C,
respectively. Gas flow rate (argon^methan 95:5) was 40 ml/min.
Evaluation
Two methods were used:
a) 5 samples of each urine specimen were hydrolyzed, and in
addition to a constant amount of 4-methoxy-3-hydroxyphenyl-
glycol (2000 ng), increasing amounts of 3^methoxy-4-hydroxy-
phenylglycol were added to 4 of them (200, 400, 600,1000 ng).
From the ratios of peak areas (3-methoxy-4-hydroxyphenyl-
glycol/4-methoxy-34iydroxyphenylglycol) a regression line was
constructed. The intersection with the abscissa gave the amount
of 3-methoxy-44iydroxyphenylglycol in the sample without
additional 3-methoxy-44iydroxyphenylglycol (fig. 1). r is a
measure of the accuracy of the determination. Our values varied
from 0.97 to 1.00.
b) From each urine specimen* only 2 samples were hydrolyzed
and only 2000 ng 4-methoxy-3-hydroxyphenylglycol added. The
resulting peak area ratios correspond to the ratios 3r-methoxyr4-
hydroxyphenylglycol/4-methoxy-3-hydroxyphenylglycol. A
calibration curve (established by adding varying amounts of
3-methoxy-4-hydroxyphenylglycol and a constant amount of
4-methoxy-3-hydroxyphenylglycol to Ringer solution and
treating it in the same way as an urinary sample) showed that
for example 2000 ng 3-methoxy-4-hydroxyphenylglycol (corre-
sponding to 2 ng injected) and 200(Xng 4-methoxy-3-hydroxy-
phenylglycol (corresponding to 2 ng injected) resulted in a ratio
of 1.0 (fig. 2).
M
1*
in
V
0.5 . 1.0
3-Methoxy-4-hydroxyphenylglycol added [μς]
Fig. 1. Regression line for the determination of 3-methoxy-4-hydroxyphenylglycpl in a urine sample according to method a),
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Fig. 2. Calibration curve for the determination of 3-methoxy-4-
hydroxyphenylglycol, using 4-methoxy-3-hydroxy-
phenylglycol as internal standard.
With lower amounts of 3-methoxy-4-hydroxyphenylglycol the
ratio, counts 3-methoxy-4-hydroxyphenylglycol/counts
4-methoxy-3-hydroxyphenylglycol, tended to be lower than
expected; with higher amounts of 3-methoxy-4-hydroxyphenyl-
glycol, it tended to be higher than expected. The deviation was
not great, but constant over a series of calibration curves. The
reason for this is the loss of a constant amount that is more
noticeable in smaller samples. This loss occurred on the column,
as could be demonstrated by injection of pure substances. To
solve this problem, we always used calibration curves for the
calculation.
Results and Discussion
The conditions for the enzymic hydrolysis are well
described by Dekirmenjian &Maas (1) and only a few
parameters were checked by us.
Repeated analysis of the same urine over a period of
five months proved that storage is possible without
deterioration (x = 1439 jug/24 h, sx = 66, η = 9). The
values showed no tendency to decrease.
The extraction with CHC13 reduced the number of
additional peaks. The loss of substance due to CHC13
extraction was less than 1%. The addition of NaCl led
to a better separation of phases and more efficient
extraction. Exact timing during the extraction (vor-
texing and centrifugation) was neces»ry for reproducible
results. The extraction with KHCO3 resulted in lower
recovery, but chromatograms showed fewer interfering
peaks and a straight baseline.
The derivatisatipn reaction according to Fellows et al.
(7),/fatora (8) and Sharpless (9), using temperatures
between 50-65 °C led to erratic results in our hands.
More reproducible results were obtained when the reac-
tion was carried out at room temperature, according to
Dekirmenjian & Maas (I). The addition of pyridine
further reduced the variability. The loss of the volatile
derivate during drying under nitrogen was very difficult
to control.
In our opinion, all these problems can.only be solved
satisfactorily by using an internal standard the chemical
structure of which guarantees a behaviour during the
analysis identical to that of the compound to be deter-
mined. External standardisation or use of other chemic-
ally unrelated compounds as internal standards makes
the procedure too susceptible to little variations and
precludes routine use.
Besides the OV-210 column, we also used the OV-17
column (Dekirmenjian &Maas (1)). On this column, a
separation of the two isomers was also possible, but in
urine extracts the peaks occurred earlier and were located
in a region of impurities. Figure 3 shows a chromatogram
on the OV-210 column.
For method a), we found a coefficient of variation of
11.3%. Five determinations of the same urine, each
containing .increased amounts of 3-methoxy-4-hydroxy-
phenylglycol, resulted in χ = 2295 Mg/24 h, sx = 259.
Five single determinations of the same urine according
to method b) (only 4-methoxy-3-hydroxyphenylglycol
added) resulted in χ = 2323 jug/24 h, sx = 155. 10 deter-
minations in duplicate with another urine, according to
method b) resulted in χ = 1845 Mg/24 h, sx = 32, coeffi-
cient of variation 1.7%. Both methods gave almost equal
results. However, in method b) the coefficient of variation
was somewhat lower. We therefore used method b) in
our subsequent determinations; method a) is not practic-
able. All determinations were carried out in duplicate
with a good correlation between the two assays (r = 0.99,
n = 197).
5 10 15
Time [ min ]
Fig. 3. Typical gas chromatogram of an extract of 0.5 ml urine.
According to the calibration curve (Fig. 2), the sample
contained 1.83 mg/1 3-methoxy-4-hydroxyphenylglycol.
A = 3rmethoxy-4-hydroxyphenylglycol
B = 4-methoxy-3-hydroxyphenylglycol.
J, Clin. Chem. Oin. Biochem./ Vol. 18,1980 / No. 9
582 Gaertner, Wiatr and Kuss: Determination of 3-methoxy-4-hydroxyphenylglycol in urine
Tab. 1. Mean 3-methoxy-4-hydroxyphenylglycol excretion in patients and controls reported in the literature, d = male, 9 = female,
s = single episode, r = recurrent, e = endogenous, ne = nonendogenous, values in Mg/24 h.
Own results: Values are also expressed in Mg/mg creatine (values in brackets), n = number of individuals. For each individual 2
to 3 separate 24 h urine samples were analysed in duplicate.
Karoum et a L,
1973(10)
Sliaw et al.,
1973(11)
Maas et al.,
1974(12)
Beckmann
et al., 1975
(13)
Deleon-Jones
et al., 1975
(14)
Josef et al.,
1976(15)
Sharpless,
1977 (9)
Ho Hist er et al.,
1978(16)
Pickar et al.,
1978(17)
Schildkraut,
1978 (4)
Taube et al.,
1978(18)
Goodwin &
Potter, 1979
(19)
Modai et al.,
1979 (20)
Own results
(Mg/mg
creatinine)
(Mg/mg
creatinine)
Controls
1863 (d)
1674 (d)
1348 (9)
1348 (9)
2740
2105 (d)
1618 (9)
2254 (d)
1591 (9)
1630 (9)
1029 (9)
1830
2001 (d)
sx = 462
(1.19; sx
1646 (9)
sx = 379
(1.57; sx
Depressed Patients with
patients primary affective
(mixed group) disorder
n = 9
n = 19
n = 21
n = 21
n = 13
n = 6
n = 5
n = ll
n = 6
n = 5
n=10
n = 18
n = ll
= 0.25)
n = 9
= 0.46)
1394 (d) n = 20
1155 (9) n = 48
1137 (9) n = 33 1032 (9)
2019 (d) n = 10
1357 (9) n = 10
1184 (9)
791 (9)
1658 n =27 1682
1310 (9)
2009 (d)
sx = 556
(1.36; sx =
1512 (9)
sx = 526
(1.41; sx =
n = 21
n = 10
n = 14
n = 23
n=13
n = 10
= 0.50)
n = 39
= 0.45)
Unipolar Bipolar Schizoaffective
depressives depressives patients
1401 (9) n = 22
1860 (9) n = 2 1590?1 (9) n = 3
8301 (9) n = 5
1161s (9) n = 14 916 (9) n = 5
1207r (9) n =13
1950e n = 16 1209 n = 1 2 1 1 4 9 n = 4
1814ne n = 13
•
1930 n =13 1360 n =10 1520 n = 4
1310 (9) n = l
2166 (d) n = 7 1339 n = 7
sx = 542 sx = 499
(1.56; sx = 0.44) (1.17; sx = 0.39)
1558 (9) n = 35
sx = 521
(1.42; sx = 0.46)
The time required for analyzing eight urine specimens
was about 48 h (using the automatic sampler), including
incubation.
For validation of our results, we compared them with
data found in the literature (see tab. 1). We also found
the sex difference in total 3-methoxy-4-hydroxyphenyl-
glycol excretion per 24 h in patients and controls. In
patients, the difference was significant (p < 0.01), whereas
in controls we only observed a trend (p < 0.1). This
difference disappears when values are expressed as /zg
3-methoxy-4-hydroxyphenylglycol/mg creatinine.
3-methoxy-4-hydroxypheriylglycol excretion in bipolar
patients (males and females) was lower (p < 0.05) than
in unipolar patients, as reported by other authors (4,13,
14,19). This also applies only for the total 3-methoxy-
4-hydroxyphenylglycol excretion, but not for 3^methoxy-
4-hydroxyphenylglycol/creatinine.
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